Table 1.
| Intrinsic Genes |
Signaling Pathways | Cell Types | Non-genetic Contexts |
Citation |
|---|---|---|---|---|
| GPX4; HRAS | xCT-GPX4 | Diffuse large B cell lymphomas; Renal cell carcinomas; Oncogenic HRAS-containing fibroblast |
7 | |
| TP53 | p53-SAT1-ALOX15 | Non-small cell lung cancer (p53−/− H1299) | 24,25 | |
| Ras | Ras-MEK | BJ-TERT/LT/ST/RASV12; Calu-1; A673; HT-1080; etc. |
6,26 | |
| FSP1 | FSP1-CoQ10-NAD(P)H | Metastatic breast cancer (MCF7); Fibrosarcoma (HT-1080); Mouse embryonic fibroblast (Pfa1) |
27,28 | |
| HSPB1 | HSF1-HSPB1-TFR1 (iron) | Cervical cancer (HeLa); Osteosarcoma (U2OS); Prostate cancer (LNCaP) |
29 | |
| Nrf2 | p62-Keap1-NRF2 (iron) | Hepatocellular carcinoma (HepG2; Hepa1-6) | 30 | |
| ATG5; ATG7 | ATG5-ATG7-NCOA4 (iron) | Mouse embryonic fibroblast (MEF); Pancreatic cancer (PANC1; PANC2.03); Fibrosarcoma (HT-1080) |
31 | |
| ATM | ATM-MTF1-Ferritin/FPN1 (iron) | Breast cancer (MDA-MB-231) | DNA damage | 32 |
| BECN1 | AMPK-BECN1-SLC7A11 | Colon adenocarcinoma (HCT116; CX-1); Fibrosarcoma (HT-1080); Cervical cancer (HeLa); Pancreatic cancer (PANC1); Non-small cell lung cancer (Calu-1) |
33 | |
| MESH1 | Renal cell carcinoma (RCC4); Non-small cell lung cancer (H1975) |
10 | ||
| RIPK3 | RIPK3-MLKL | Recurrent HER2 driven tumor (mouse) | 34 | |
| TAZ | TAZ-EMP1-NOX4 | Renal cell carcinoma (RCC4); Renal cell adenocarcinoma (786O) |
Cell density | 35 |
| TAZ | TAZ-ANGPTL4-NOX2 | Recurrent ovarian cancer (mouse) | Cell density | 28 |
| YAP | ECAD-NF2-YAP | Epithelial cancer (MDA-MB-231; H1650; HCT116; HepG2; PC9; BT474); Patient-derived malignant mesothelioma (211H; Meso33, etc) |
Cell density and contact | 36 |